NEW YORK, April 21, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding HB Fuller Co. (NYSE: FUL), Cytec Industries Inc. (NYSE: CYT), NewMarket Corp. (NYSE: NEU), Senomyx Inc. (NASDAQ: SNMX), and Balchem Corp. (NASDAQ: BCPC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1346-100free
--
HB Fuller Co. Analyst Notes
On April 10, 2014, HB Fuller Co. (HB Fuller) reported that its Board of Directors has voted to increase the Company's regular quarterly dividend from $0.10 per share of common stock to $0.12 per share of common stock. According to the Company, this indicates a 20% increase over the previously announced quarterly dividend and marks the 45th consecutive year in which HB Fuller increased its dividend. HB Fuller added that the dividend is payable on May 8, 2014 to shareholders of record at the close of business on April 24, 2014. The full analyst notes on HB Fuller Co. are available to download free of charge at:
http://www.analystsreview.com/1346-FUL-21Apr2014.pdf
--
Cytec Industries Inc. Analyst Notes
Cytec Industries Inc. (Cytec) posted on the "Upcoming Events" page on its website that it will participate in the following conferences during April 2014: EXPOMIN 2014 in Santiago, Chile, from April 21-25, 2014; and ChinaPlas 2014 in Shanghai, China, from April 23-26, 2014. The full analyst notes on Cytec Industries Inc. are available to download free of charge at:
http://www.analystsreview.com/1346-CYT-21Apr2014.pdf
--
NewMarket Corp. Analyst Notes
On April 15, 2014, NewMarket Corp.'s (NewMarket) stock increased 0.54%, ending the day at $388.25. Over the previous five trading sessions, shares in NewMarket gained 0.63%, compared to the Dow Jones Industrial Average which also advanced 0.04% during the same period. The full analyst notes on NewMarket Corp. are available to download free of charge at:
http://www.analystsreview.com/1346-NEU-21Apr2014.pdf
--
Senomyx Inc. Analyst Notes
On April 9, 2014, Senomyx Inc. (Senomyx) announced that it has entered into a new collaborative agreement with PepsiCo, Inc. (PepsiCo) regarding Senomyx's Salt Taste Program. The Company stated that this new partnership will support the Company's continued work to identify flavors with modifying properties intended to restore the desired salty taste in products with reduced salt (sodium chloride). Senomyx informed that in accordance with the new agreement, PepsiCo will provide research funding for the Salt Taste Program for 2014. John Poyhonen, President and CEO of Senomyx, commented, "We are pleased to establish this new type of research agreement, which provides research funding to Senomyx while retaining our ability to add potential new flavor offerings to our direct sales portfolio." The full analyst notes on Senomyx Inc. are available to download free of charge at:
http://www.analystsreview.com/1346-SNMX-21Apr2014.pdf
--
Balchem Corp. Analyst Notes
On April 15, 2014, Balchem Corp.'s (Balchem) stock declined 0.50%, ending the day at $62.28. For the past month, shares in Balchem increased 13.35%, compared to the Nasdaq Composite which declined 4.98% during the same period. The full analyst notes on Balchem Corp. are available to download free of charge at:
http://www.analystsreview.com/1346-BCPC-21Apr2014.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
